Focus Partners Advisor Solutions LLC Buys 8,105 Shares of Bruker Corporation $BRKR

Focus Partners Advisor Solutions LLC grew its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 101.8% during the second quarter, HoldingsChannel reports. The firm owned 16,069 shares of the medical research company’s stock after purchasing an additional 8,105 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in Bruker were worth $662,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of BRKR. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Bruker by 81.2% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 29,826 shares of the medical research company’s stock valued at $1,245,000 after purchasing an additional 13,367 shares in the last quarter. Diversified Trust Co bought a new stake in shares of Bruker during the 1st quarter valued at about $378,000. Allspring Global Investments Holdings LLC boosted its stake in shares of Bruker by 1.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 216,866 shares of the medical research company’s stock valued at $8,757,000 after purchasing an additional 2,286 shares in the last quarter. KBC Group NV boosted its stake in shares of Bruker by 0.8% during the 1st quarter. KBC Group NV now owns 44,715 shares of the medical research company’s stock valued at $1,866,000 after purchasing an additional 349 shares in the last quarter. Finally, New York State Teachers Retirement System boosted its stake in shares of Bruker by 0.8% during the 1st quarter. New York State Teachers Retirement System now owns 37,115 shares of the medical research company’s stock valued at $1,549,000 after purchasing an additional 300 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Trading Up 0.2%

Shares of NASDAQ BRKR opened at $38.72 on Wednesday. The firm’s 50 day moving average price is $34.24 and its 200-day moving average price is $37.00. The company has a market cap of $5.87 billion, a PE ratio of 74.46, a P/E/G ratio of 5.44 and a beta of 1.20. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $64.64. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61.

Bruker (NASDAQ:BRKR) last issued its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $797.40 million during the quarter, compared to the consensus estimate of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.The company’s quarterly revenue was down .4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.52 EPS. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, equities research analysts expect that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Tuesday, September 23rd. Bruker’s dividend payout ratio is currently 38.46%.

Insider Buying and Selling at Bruker

In other news, Director Cynthia M. Friend sold 3,535 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $32.25, for a total transaction of $114,003.75. Following the completion of the transaction, the director directly owned 18,016 shares of the company’s stock, valued at $581,016. The trade was a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 27.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BRKR. Stifel Nicolaus set a $40.00 price target on shares of Bruker and gave the company a “hold” rating in a research report on Tuesday, August 5th. Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a research report on Wednesday, October 8th. Barclays lowered their price target on shares of Bruker from $43.00 to $40.00 and set an “overweight” rating for the company in a research report on Thursday, October 2nd. Wells Fargo & Company lowered their price target on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating for the company in a research report on Tuesday, August 5th. Finally, Citigroup lowered their price target on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a research report on Monday, August 4th. Five analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $51.00.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.